USD
$0.00
(0.00%
)At Close (As of Sep 26, 2025)
$6.36M
Market Cap
-
P/E Ratio
-1.41
EPS
$3.35
52 Week High
$1.20
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | -$2M |
Total Revenue | $4.5M |
Cost Of Revenue | $6.5M |
Costof Goods And Services Sold | $6.5M |
Operating Income | -$4.6M |
Selling General And Administrative | $1.8M |
Research And Development | $284K |
Operating Expenses | $2.6M |
Investment Income Net | - |
Net Interest Income | -$147K |
Interest Income | $6.6K |
Interest Expense | $154K |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $2.6M |
Income Before Tax | -$4.7M |
Income Tax Expense | -$4.7T |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$4.7M |
Comprehensive Income Net Of Tax | - |
Ebit | -$4.6M |
Ebitda | -$2M |
Net Income | -$4.7M |
Field | Value (USD) |
---|---|
Total Assets | $15M |
Total Current Assets | $3.3M |
Cash And Cash Equivalents At Carrying Value | $627K |
Cash And Short Term Investments | $627K |
Inventory | $2.3M |
Current Net Receivables | $281K |
Total Non Current Assets | $12M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $7.1M |
Intangible Assets Excluding Goodwill | $7.1M |
Goodwill | -$392K |
Investments | - |
Long Term Investments | - |
Short Term Investments | $627B |
Other Current Assets | $96K |
Other Non Current Assets | - |
Total Liabilities | $7.1M |
Total Current Liabilities | $5M |
Current Accounts Payable | $225K |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $2.2M |
Total Non Current Liabilities | $2.1M |
Capital Lease Obligations | $39K |
Long Term Debt | $1.4M |
Current Long Term Debt | $2.2M |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $3.6M |
Other Current Liabilities | $1.8M |
Other Non Current Liabilities | - |
Total Shareholder Equity | $7.7M |
Treasury Stock | - |
Retained Earnings | -$44M |
Common Stock | $33K |
Common Stock Shares Outstanding | $17M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$466K |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $2.6M |
Capital Expenditures | $292K |
Change In Receivables | - |
Change In Inventory | $1.6M |
Profit Loss | - |
Cashflow From Investment | -$292K |
Cashflow From Financing | $27K |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$4.7M |
Field | Value (USD) |
---|---|
Gross Profit | -$2M |
Total Revenue | $4.5M |
Cost Of Revenue | $6.5M |
Costof Goods And Services Sold | $6.5M |
Operating Income | -$4.6M |
Selling General And Administrative | $1.8M |
Research And Development | $284K |
Operating Expenses | $2.6M |
Investment Income Net | - |
Net Interest Income | -$147K |
Interest Income | $6.6K |
Interest Expense | $154K |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $2.6M |
Income Before Tax | -$4.7M |
Income Tax Expense | -$4.7T |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$4.7M |
Comprehensive Income Net Of Tax | - |
Ebit | -$4.6M |
Ebitda | -$2M |
Net Income | -$4.7M |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
China Pharma Holdings, Inc. is a leading Chinese enterprise engaged in the development, manufacturing, and marketing of a diverse range of generic and branded pharmaceutical and biochemical products. Catering primarily to hospitals and private retailers within the People's Republic of China, the company focuses on delivering high-quality healthcare solutions. Headquartered in Haikou, China, CPHI is strategically positioned to leverage the growing pharmaceutical market in the region, thereby enhancing its competitive edge and expanding its market presence.